Morse, Michael A. http://orcid.org/0000-0002-5725-4533
Gwin, William R. III http://orcid.org/0000-0001-6314-0965
Mitchell, Duane A.
Funding for this research was provided by:
Sumitomo Dainippon Pharma Oncology, Inc.
Article History
Accepted: 24 December 2020
First Online: 29 January 2021
Declarations
:
: Medical writing assistance was funded by Sumitomo Dainippon Pharma Oncology, Inc.
: MAM is a consultant/advisory board member for Roche/Genentech, AstraZeneca/Medimmune, Celldex, Eli Lilly, and Gritstone and has received research funding from Merck, BMS, Etubics, and Alphavax. WRG and DAM declare that they have no conflict of interest.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors were involved in the development of the content and direction of this article. Additionally, all authors revised it critically for important intellectual content; approved the final version; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.